Summary
Bristol-Myers Squibb Company (BMY) reported a significant decline in net sales for the quarter and six months ended June 30, 2012, primarily driven by the loss of exclusivity for key products like Plavix and Avapro/Avalide. This resulted in a decrease in net earnings attributable to Bristol-Myers Squibb Company from $902 million in Q2 2011 to $645 million in Q2 2012, and from $1.888 billion in the first six months of 2011 to $1.746 billion in the same period of 2012. Despite the revenue pressure from patent expirations, the company continues to invest in its pipeline and has made strategic acquisitions, including the agreement to acquire Amylin Pharmaceuticals for approximately $5.3 billion. Management's strategy focuses on growing newer key marketed products, advancing its R&D pipeline in immuno-oncology, cardiovascular/metabolic disease, and virology, and expanding its presence in emerging markets. The company also highlighted positive developments in key products like Eliquis, Yervoy, and Orencia, and provided updates on ongoing clinical trials and regulatory reviews.
Financial Highlights
57 data points| Revenue | $4.44B |
| Cost of Revenue | $1.25B |
| Gross Profit | $3.20B |
| R&D Expenses | $962.00M |
| SG&A Expenses | $1.00B |
| Operating Expenses | $3.38B |
| Interest Expense | $41.00M |
| Net Income | $645.00M |
| EPS (Basic) | $0.38 |
| EPS (Diluted) | $0.38 |
| Shares Outstanding (Basic) | 1.68B |
| Shares Outstanding (Diluted) | 1.70B |
Key Highlights
- 1Net sales decreased by 18% to $4.44 billion for the three months ended June 30, 2012, compared to $5.43 billion in the prior year, largely due to patent expirations of Plavix and Avapro/Avalide.
- 2Net earnings attributable to Bristol-Myers Squibb Company fell to $645 million ($0.38 per diluted share) for the quarter ended June 30, 2012, down from $902 million ($0.52 per diluted share) in the same period of 2011.
- 3The company announced an agreement to acquire Amylin Pharmaceuticals for approximately $5.3 billion, signaling a strategic move into the diabetes and metabolic diseases market.
- 4Research and development expenses increased slightly to $962 million in Q2 2012 from $923 million in Q2 2011, reflecting continued investment in pipeline development.
- 5Cash, cash equivalents, and marketable securities stood at $8.77 billion as of June 30, 2012, providing a strong liquidity position.
- 6The company is actively managing its portfolio, with new product launches and pipeline advancements in key therapeutic areas such as immuno-oncology and cardiovascular/metabolic disease, despite facing significant patent cliffs.
- 7Costs associated with restructuring and litigation expenses were noted, with a decrease in restructuring provisions and a litigation recovery related to Plavix.
- 8Despite revenue challenges, the company's strategy includes expanding its presence in emerging markets and focusing on the growth of its newer key marketed products.